Vitamin D Supplementation in Multiple Sclerosis

• ClinicalTrials.gov Identifier: NCT01490502
• Recruitment Status: Completed
• First Posted: December 13, 2011
• Results First Posted: September 28, 2022
• Last Update Posted: September 28, 2022
• Sponsor: Johns Hopkins University
• Collaborators: Oregon Health and Science University; University of California, San Francisco; Washington University School of Medicine; Icahn School of Medicine at Mount Sinai; University of Pennsylvania; Yale University; The Cleveland Clinic; University of Rochester; Stanford University; University of Virginia; Swedish Medical Center; Anne Arundel Health System Research Institute; Columbia University; University of Massachusetts, Worcester; Dignity Health
• Information provided by (Responsible Party): Johns Hopkins University

Tracking Information

• First Submitted Date: December 6, 2011
• First Posted Date: December 13, 2011
• Results First Submitted Date: May 13, 2022
• Results First Posted Date: September 28, 2022
• Last Update Posted Date: September 28, 2022
• Actual Study Start Date: March 2012
• Actual Primary Completion Date: May 15, 2021 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: September 12, 2022)

Proportion of Subjects That Experience a Relapse [ Time Frame: 2 years ]

Confirmed relapse defined as new or worsening symptoms referable to the central nervous system, lasting at least 24 hours, occurring at least 30 days since the prior attack, accompanied by worsening of the EDSS (>= 0.5 points) or in the Functional Systems (FS) scales (2 points on at least one FS scale or 1 point on >= two FS scales).

• Original Primary Outcome Measures (submitted: December 12, 2011): Proportion of subjects that experiences a relapse [ Time Frame: 2 years ]

Current Secondary Outcome Measures (submitted: September 12, 2022)

• Annualized Relapse Rate [ Time Frame: 2 years ]
  Average relapses per year
• Number of Relapses Requiring Treatment [ Time Frame: 2 years ]
• Number of New or Enlarging T2 Lesions [ Time Frame: 2 years ]
• Proportion of Participants With Sustained Disability Progression [ Time Frame: 2 years ]
  The Expanded Disability Status Scale (EDSS) is an ordinal clinical rating scale based on a standard neurological examination and is used to measure global neurologic impairment in people with multiple sclerosis (MS). It ranges from a minimum of 0.0 (normal examination) to 10.0 (death due to MS) in half-point increments. A participant will be considered to have had sustained progression of disability if there is an increase in the EDSS score at month 12 by at least 1.0 point that is confirmed on the final examination one year later (month 24).
• Change in Multiple Sclerosis Functional Composite (MSFC) Score [ Time Frame: 2 years ]
  The Multiple Sclerosis Functional Composite (MSFC) is a three-part measure of disability for people with multiple sclerosis, including measures of leg function/ambulation, arm/hand function and cognitive function. The three independent measures have different units. We take the reciprocal of the arm/hand function test, and then convert all measures to Z-scores. The average of the Z-scores from each measure yields the MSFC composite Z-score. A Z-score of 0 represents the population mean and positive scores indicate less disability. The MSFC was measured at baseline and up to 4 more times over 2 years.
• Change in Low-contrast Acuity [ Time Frame: 2 years ]
  Low-contrast acuity was measured as binocular vision on a 2.5% Sloan chart at a distance of 2 meters. The chart is used to test the ability to discriminate gradually smaller gray letters with a 2.5% contrast level against a white background. The low-contrast acuity measure is scored as total letters read and ranges from 0 (no letters read) to 60 (all letters read). Low-contrast acuity was measured at baseline and up to 4 more times over 2 years and higher scores indicate better low-contrast acuity.
• Change in Health-related Quality of Life [ Time Frame: 2 years ]
  The Functional Assessment of Multiple Sclerosis (FAMS) questionnaire is the quality of life (QOL) instrument used in this trial. It consists of 44 questions and the total score has a possible range of 0 to 176, with higher scores indicating better QOL. The FAMS questionnaire was obtained at baseline and up to 4 more times over 2 years.
• Change in Brain Parenchymal Volume [ Time Frame: 2 years ]
• Change in Normalized Gray Matter Volume [ Time Frame: 2 years ]
• Change in Cortical Thickness [ Time Frame: 2 years ]
  Unable to analyze this outcome measure
• Development of Hypercalcemia [ Time Frame: 2 years ]
• Development of Nephrolithiasis [ Time Frame: 2 years ]

Original Secondary Outcome Measures (submitted: December 12, 2011)

• Annualized relapse rate [ Time Frame: 2 years ]
• Number of relapses requiring treatment [ Time Frame: 2 years ]
• Number of new T2 lesions [ Time Frame: In the two-year study, compared to baseline ]
• Occurrence of sustained disability progression [ Time Frame: At years 1 and 2, compared to baseline ]
  A patient will be considered to have had sustained progression of disability if there is an increase in the Expaned Disability Status Scale score at month 12 by at least 1.0 point that is confirmed on the final examination one year later.
• Change in MS Functional Composite Score [ Time Frame: Over the two-year study compared to baseline ]
• Change in low-contrast acuity [ Time Frame: Over the two-year study compared to baseline ]
• Change in health-related quality of life [ Time Frame: Over the two-year study compared to baseline ]
• Change in brain parenchymal volume [ Time Frame: Over the two-year study compared to baseline ]
• Change in normalized gray matter volume [ Time Frame: Over the two-year study compared to baseline ]
• Change in cortical thickness [ Time Frame: Over the two year study compared to baseline ]
• Development of hypercalcemia/related adverse effects [ Time Frame: 2 years ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Vitamin D Supplementation in Multiple Sclerosis
• Official Title: A Randomized Controlled Trial of Vitamin D Supplementation in Multiple Sclerosis

Brief Summary

Low vitamin D levels have been shown to increase a person's risk of developing multiple sclerosis (MS), and patients with MS who have lower vitamin D levels are at increased risk of having attacks. However, it is not known if giving supplemental vitamin D to those with MS reduces the risk of attacks, and some research suggests that vitamin D could even be harmful to people with MS.

In this clinical trial, patients with relapsing-remitting MS will receive high-dose or low-dose oral vitamin D in addition to an approved therapy for MS, glatiramer acetate. Patients will be evaluated for two years, and the effect of high-dose vitamin D supplementation on the rate of MS attacks and on the number of new lesions and change in brain volume on MRI will be determined. Establishing this association will have major implications for the treatment of individuals with MS throughout the world.

Detailed Description

Vitamin D insufficiency has recently emerged as a risk factor for susceptibility to multiple sclerosis (MS). The investigator's observational data suggest that lower vitamin D levels in patients with relapsing-remitting MS are associated with a higher subsequent relapse rate. However, it is unknown if providing vitamin D supplementation to such patients leads to a reduction in the risk of an exacerbation. Historically, several nutritional supplements that appeared to be helpful in observational studies of various diseases did not demonstrate a benefit or were harmful in randomized trials. Further, a vitamin D response element was recently identified in the promoter region of Human Leukocyte Antigen (HLA)-DRB1*15, the gene believed to be critical to initiating the autoimmune response in MS, and 1, 25-dihydroxyvitamin D3 increases the expression of the gene in vitro, suggesting that vitamin D supplementation could even be harmful in established MS.

This is a randomized, double-blind trial of high- versus low-dose vitamin D3 supplementation as an add-on to glatiramer acetate in 172 patients with relapsing-remitting MS. Subjects will be randomized to 600 IU or 5000 IU of oral vitamin D3 daily for two years. A standardized brain MRI scan will be performed at baseline and at the end of the first and second years. The impact of high-dose vitamin D supplementation on the number of relapses, the number of new lesions on brain MRI, and the change in brain volume will be assessed. Establishing these associations will have major implications for the treatment of patients with MS throughout the world and will provide rationale for further investigations of the role of vitamin D in the immunopathogenesis of MS, possibly leading to the identification of new therapeutic targets.

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Relapsing Remitting Multiple Sclerosis

Intervention

Drug: Vitamin D3

Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).

Study Arms

• Active Comparator: Low-dose vitamin D3
  Intervention: Drug: Vitamin D3
• Active Comparator: High-dose vitamin D3
  Intervention: Drug: Vitamin D3

• Publications *: Bhargava P, Cassard S, Steele SU, Azevedo C, Pelletier D, Sugar EA, Waubant E, Mowry EM. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials. 2014 Nov;39(2):288-93. doi: 10.1016/j.cct.2014.10.004. Epub 2014 Oct 12.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: December 12, 2011): 172
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: May 15, 2021
• Actual Primary Completion Date: May 15, 2021 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Must meet Magnetic Resonance Imaging in MS (MAGNIMS) criteria for relapsing-remitting MS
• Age 18 to 50 years
• Expanded Disability Status Scale (EDSS) score ≤ 4.0
• MS disease duration ≤ 10 years if McDonald Relapse Remitting Multiple Sclerosis (RRMS;) ≤ 1 year if meets MAGNIMS RRMS criteria but not McDonald RRMS criteria
• If the patient meets the McDonald RRMS criteria (rather than McDonald Clinically

Isolated Syndrome (CIS) that is now classified as MAGNIMS MS):

• Must have had one clinical attack in past two years and at least one new silent T2 or gadolinium-enhancing lesion on brain MRI within the past year OR
• Must have had two clinical attacks in past two years, one of which occurred in the past year
• Females of child-bearing age must be willing to use at least one form of pregnancy prevention throughout the study.
• Must have had a 25-hydroxyvitamin D level of ≥ 15 ng/mL within past 30 days
• Must be willing to stop taking additional supplemental vitamin D, except as part of a multivitamin, and must be willing to not take cod liver oil.

Exclusion Criteria:

• Not be pregnant or nursing
• No ongoing renal or liver disease
• No known history of nephrolithiasis, hypercalcemia, sarcoidosis or other serious chronic illness including cancer (other than basal cell or squamous cell carcinoma of the skin), cardiac disease, or HIV.
• No ongoing hyperthyroidism or active infection with Mycobacterium species
• No known gastrointestinal disease (ulcerative colitis, Crohn's disease, celiac disease/gluten intolerance) or use of medications associated with malabsorption.
• No history of self-reported alcohol or substance abuse in past six months.
• No prior history of treatment with rituximab, any chemotherapeutic agent, or total lymphoid irradiation. No treatment in the past six months with natalizumab, fingolimod, or fumarate. If patient has received glatiramer acetate, they have not been exposed to more than three months of treatment. No treatment with other unapproved therapies for MS.
• No use of interferon beta or glatiramer acetate therapy for one month prior to screening
• No use of more than 1,000 IU vitamin D3 daily in the three months prior to screening
• No condition that would limit the likelihood of completing the MRI procedures
• No use of thiazide diuretics, digoxin, diltiazem, verapamil, cimetidine, heparin, low-molecular weight heparin, phenytoin, phenobarbital, carbamazepine, routine corticosteroids (eg scheduled monthly steroids, daily, etc), rifampin, or cholestyramine.
• No steroids within a month of screening.
• Not suicidal at screening visit (ineligible if answers "yes" to question 1 of screening Columbia Suicide Severity Rating Scale (C-SSRS) in PAST 2 MONTHS; or answers "yes" to questions 2-5 on C-SSRS for PAST 6 MONTHS; or answers "yes" to suicidal attempts or preparatory attempts in PAST 5 YEARS , http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225130.pdf).
• Serum calcium >0.2 mg/dL above upper limit of normal.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 50 Years (Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT01490502
• Other Study ID Numbers: NA_00049137
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Johns Hopkins University
• Original Responsible Party: Ellen M. Mowry, Johns Hopkins University, Assistant Professor of Neurology
• Current Study Sponsor: Johns Hopkins University
• Original Study Sponsor: Same as current

Collaborators

• Oregon Health and Science University
• University of California, San Francisco
• Washington University School of Medicine
• Icahn School of Medicine at Mount Sinai
• University of Pennsylvania
• Yale University
• The Cleveland Clinic
• University of Rochester
• Stanford University
• University of Virginia
• Swedish Medical Center
• Anne Arundel Health System Research Institute
• Columbia University
• University of Massachusetts, Worcester
• Dignity Health

Investigators

• Principal Investigator: Ellen M Mowry, MD, MCR; Johns Hopkins University

• PRS Account: Johns Hopkins University
• Verification Date: September 2022